Protein A from Staphylococcus aureus Cowan 1 (Staph A) and intact staphylococci induce histamine release from human basophils (23, 25, 26) . It has been suggested that the activation of human basophils induced by Staph A is mediated by the interaction with the cell surface-bound immunoglobulin G (IgG) (26) . We have found a significant correlation between the maximum percent histamine release induced by anti-IgE and that induced by Staph A, which suggests that these two release mechanisms have a common triggering event (23) . However, the mechanism of basophil activation induced by staphylococci and Staph A has yet to be defined.
Staph A is known to bind specifically to the FcY region of human IgG subclasses 1, 2, and 4 (3) . Binding to other immunoglobulin isotypes was initially reported to be minimal (15, 36) . More recently, however, it has been shown that Staph A also reacts with a structure located in the Fab region of immunoglobulin which is shared by human IgM, IgE, IgG, and IgA (7, 9) . Unlike rabbit IgG, which reacts with Staph A through the FcY region alone, human IgG can react with Staph A via both the Fab and the Fc regions, and the Staph A-binding Fab region is shared by a proportion of human IgE, IgM, and IgA (7, 9) .
Human basophils possess specific, distinct membrane receptors for the Fc', and Fc, portions of IgE and IgG (12, * Corresponding author. 13 ). Anti-IgE (rabbit anti-Fc,) and anti-IgG (rabbit anti-FcY) induce histamine secretion by cross-linking membranebound IgE and IgG, respectively (4, 10) . Therefore, the possibility exists that Staph A and S. aureus also induce histamine release from human basophils by cross-linking membrane-bound immunoglobulins.
The experiments described here were designed to investigate the mechanism by which Staph A and Staph Acontaining staphylococci activate basophils. The results indicate that Staph A and S. aureus Cowan 1 induce the activation of human basophils by cross-linking of sites on the F(ab')2 portion of IgE or IgG or both present on the cell surface. Histamine release assay. After informed consent was obtained, blood was drawn into a final concentration of 0.008 M EDTA and 1.1% dextran 70 and allowed to sediment for 90 min at 22°C (21) . The leukocyte-rich upper layer was drawn off, pelleted (200 x g, 4°C, 8 min), and washed as previously described (19) . A 0.4-ml sample of the cell suspension (106 to 2.5 x 106 cells per tube) was placed in Falcon polyethylene tubes (12 by 75 mm; Becton Dickinson Labware, Oxnard, Calif.) and warmed to 37°C; 0.2 ml of each stimulus for release was prewarmed and added to the cells, and incubation was continued at 37°C for 45 min (22) . After centrifugation (1,000 x g, 22°C, 2 min), the cell-free supernatants were assayed for histamine by an automated fluorometric technique developed by Siraganian (20, 38) . The net percent release was calculated from the total histamine released from cell aliquots by lysis with 2% perchloric acid minus the histamine released spontaneously from unstimulated samples (17) . Spontaneous histamine release in PC was always less than 5% of the total histamine. All experiments were done with cells from at least four separate donors, and each experiment was performed in duplicate or triplicate, with less than 10% variation between replicates.
Purification of human monoclonal and polyclonal IgE proteins. IgE myeloma proteins ADZ (35) and PS (kindly donated by A. Sehon) were purified from the patient sera by repeated gel filtration on Sepharose G-200 followed by elution through a Sepharose CL-4B column. Human polyclonal IgE (isolated by affinity chromatography from the serum of a patient) containing approximately 50,000 IU of IgE was further purified by repeated gel filtration on an Ultrogel AcA 34 column (14) . Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of purified human monoclonal and polyclonal IgE proteins demonstrated a single protein with a molecular weight of 180,000 to 200,000. Analysis by radioimmunoassay showed no IgG, IgM, or IgA contamination (30, 32) .
Purification of monoclonal IgM proteins. Monoclonal IgM proteins reactive (IgMR) and nonreactive (IgMNR) with the alternative site of Staph A were isolated from the serum of two patients with Waldenstrom's macroglobulinemia by repeated euglobulin precipitation with distilled water followed by gel filtration on Sephadex G-200. IgMR and IgMNR proteins were freed from any contaminating IgG by elution through a column containing rabbit antibodies against human -y-chain coupled to CNBr-activated Sepharose CL-4B (33) . Purification of HIgG and RIgG. Human (HIgG) and rabbit (RIgG) polyclonal IgGs were prepared by precipitation of normal human or rabbit serum with 50% saturated ammonium sulfate followed by chromatography on a DEAEcellulose column equilibrated with 0.01 M phosphate buffer (pH 7.9) as previously described (33) . Nonretained protein was collected.
Anti-immunoglobulin antisera. The preparation and characterization of affinity-purified rabbit antibodies directed against human fy-chain have been described in detail elsewhere (28, 31) . Briefly, the antisera were rendered monospecific by repeated solid-phase absorption with appropriate immunoglobulin class determinants. After these absorptions, purified antibodies specific for human -y-chain determinants were obtained by affinity chromatography. The specificity of the anti-human -y-chain antiserum was checked by double diffusion in agarose, by immunofluorescence on bone marrow from patients with IgG, IgD, and IgA myelomas, and by radioimmunoassay performed in polyvinyl plates (Dynatech Laboratories, Inc., Alexandria, Va. performed by the chloramine-T method (6) . lodination of Staph A. Staph A (1 mg/ml) was iodinated with different concentrations of KI (0.001 to 10 mg/ml) in the presence of chloramine-T (1.6 mg/ml), and the reaction was stopped by the addition of sodium metabisulfite (4.8 mg/ml). lodinated Staph A was then separated on a Sephadex G-25 column (6, 28, 33, 39) .
Solid-phase protein-binding assay. The ability of Staph A and hyperiodinated Staph A to react with RIgG, HIgG, and human IgMR was evaluated by a solid-phase binding assay performed in polyvinyl plates (Dynatech). For this purpose, microtiter plate wells were filled with Staph A at a concentration of 2 ,ug/ml. After incubation overnight at 22°C, the coating solution was removed, and wells were washed individually three times with phosphate-buffered saline (pH 7.8), and then 10% bovine serum albumin (BSA) in phosphate-buffered saline was added to the wells and left for 6 h to saturate any remaining protein-binding surface. After three washes with phosphate-buffered saline, the labeled reagents to be assayed were added to wells and allowed to incubate overnight at 22°C. Thereafter, the plates were washed three times with 1% BSA in phosphate-buffered saline and eight times with running tap water. The individual wells were separated, and the bound radioactivity was determined.
Staphylococci. S. aureus Cowan 1 and Wood 46 were obtained from the National Collection of Type Cultures (London). The bacteria were killed by incubation with 0.5% formaldehyde (3 h, 22°C), heat treated (3 min, 80°C), washed, and finally stored in small aliquots at -80°C. The bacteria were counted in a Neubauer chamber (33 treatment. These findings suggest that activation of basophils induced by Staph A is not mediated by interaction through the classical site of the protein.
The alternative F(ab')2-binding site on Staph A is responsible for S. aureus Cowan 1-induced activation of human basophils. The role of F(ab')2-binding regions of Staph A in the activation of human basophils induced by Staph Acontaining S. aureus was investigated next. In a first series of experiments, we studied the effect on Staph A-induced basophil activation of molecules that exhibit Fcy-Staph A reactivity alone, such as RIgG, those that exhibit F(ab')2-Staph A reactivity alone, such as IgMR, and those with both Fc,, and F(ab')2 reactivity, such as HIgG (7, 9, 33) . As a control, the effect of IgMNR was also evaluated. Both HIgG and IgMR dose dependently inhibited Staph A-induced histamine release, whereas RIgG and IgMNR had no such effect (Fig. 4A) . In a parallel series of experiments, we tried to inhibit selectively the Fc and F(ab')2 reactivity of intact S. aureus by preincubation with the immunoglobulins mentioned above (Fig. 4B) . The results were essentially similar to those obtained with purified Staph A. The findings indicate that both Staph A and S. aureus induce histamine release, presumably by binding through the alternative site to immunoglobulins present on human basophils.
Cross-desensitization between S. aureus, Staph A, anti-IgE, and anti-IgG. We have previously shown an excellent cor- relation between maximal release caused by anti-IgE and that caused by Staph A (23) . The relationship between anti-IgE and Staph A was further examined to test for cross-desensitization between anti-IgE, anti-IgG, and Staph A. Leukocytes were treated with anti-IgE (1 jig/ml), Staph A (10 ,ug/ml), or anti-IgG (100 j.g/ml) in P-EDTA for 30 min at 37°C. At the end of incubation, cells were washed and suspended in PC. Cells preincubated with P or with anti-IgG released histamine normally with anti-IgE (Fig. 5 ). In contrast, leukocytes preincubated with anti-IgE released less than 10% histamine. Cells desensitized to Staph A released 60 to 80% less histamine than did control cells. Basophils of this donor released histamine (36% of total content) when challenged with anti-IgG (100 jig/ml) (data not shown).
In reverse experiments, cells were preincubated with anti-IgG, Staph A, or anti-IgE in P-EDTA before challenge with Staph A. As expected, when Staph A-pretreated cells were challenged with Staph A they had lost their ability to release with the homologous stimulus (Fig. 6) . Preincubation with anti-IgG and anti-IgE, respectively, partly and almost completely desensitized basophils. Thus, it appears that the releasing activity property of Staph A is mediated mainly by interaction with IgE and partly by interaction with IgG present on the basophil membrane (12, 13) .
A second line of evidence that Staph A induces histamine release by binding to IgE is based on its different capacity to induce histamine release from basophils from which IgE had been dissociated versus those to which IgE had been restored (27) . IgE is removed from basophil receptors by brief exposure to low pH; it is restored by exposing the unoccupied receptors to IgE. Lactic acid-induced dissociation of IgE from basophils markedly reduced anti-IgE-induced release and completely eliminated Staph A-induced release (Fig. 7) . When basophils from which IgE had been dissoci- 
DISCUSSION
The results of the present study indicate that soluble Staph A-containing bacteria such as S. aureus Cowan 1 induce histamine release from human basophils. S. aureus Wood 46, which does not synthesize Staph A, failed to activate these cells. The releasing activity of both Staph A and S. aureus Cowan 1 appears to be mediated by interaction of the alternative nonimmune F(ab')2-binding site with IgE or IgG or both present on human basophils. Another Staphylococcus component, Staph A-enterotoxin A, which also activates human lymphocytes (29) and which has been found to contaminate some Staph A preparations (40), is not responsible for the releasing property of Staph A.
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STAPHA ,+/. Effect of desensitization to one stimulus on the response to a second stimulus. Cells were desensitized to anti-IgG (100 ,g/ml), Staph A (10 ,ug/ml), or anti-IgE (1 ,ug/ml) by preincubation with the stimuli in P-EDTA for 40 Hyperiodination of Staph A and inhibitory experiments with immunoglobulins indicated that the F(ab')2 region rather than the Fc-binding region is responsible for the activating property of the molecule.
In addition to the classical FcY-Staph A interaction, several data indicate the existence of a common and variably expressed Staph A reactivity in at least four (IgG, IgM, IgA, and IgE) of five human immunoglobulins (7, 14) . The alternative reactivity involves protein fragment B (the one involved in the classical reactivity) (8) and a structure located in the F(ab')2 fragment of Staph A-reactive immunoglobulins (9, 33) . It crosses species (9) and does not correlate with the light-chain type, subclass characteristics, or allotypic markers (7) . Although there is no direct evidence to support an association between certain invariant or subgroup (framework) regions of the variable domain and the alternative Staph A reactivity, this association cannot be excluded (7) . While the Fc fragment of IgG is monovalent in its reaction with Staph A, the alternative protein reactivity is bivalently expressed in F(ab')2 fragments of human immunoglobulins (40) . It is therefore possible that S. aureus Cowan 1 and Staph A cross-link some of the IgE on human basophils. This is borne out by the previously reported (23) correlation between the maximum percent histamine release induced by anti-IgE and that induced by Staph A. Furthermore, the possibility cannot be excluded that Staph A binds to the F(ab')2 fragments of some of the IgG bound on basophil membranes (12, 13) .
The alternative Staph A reactivity is essential for the occurrence of precipitation in vitro between IgG and Staph A as it provides the crucial link between Staph A and IgG for the formation of the three-dimensional lattice required for precipitation (8 Fab-associated reactivity (9) . An interaction between the alternative Staph A-binding site and surface IgM has been found to be mainly responsible for the mitogenicity of insolubilized Staph A (Staph A linked to Sepharose beads or present on the cell wall of S. aureus Cowan 1 bacteria) on human lymphocytes (29) . Our results suggest that the alternative Staph A-binding activity is responsible for the activation of human basophil leukocytes to release inflammatory mediators. Therefore, the alternative Staph A-binding activity may represent an example of biologically significant interaction between bacterial antigens and immunoglobulins. Such an interaction has the potential to trigger defensive effector systems. It has been recently shown that other bacteria, such as Streptococcus haemolyticus, synthesize a protein, distinct from Staph A, which also binds to the F(ab')2 fragment of some human polyclonal immunoglobulins (2). Therefore, it is possible that the alternative Staph A reactivity represents some kind of primitive, broadspectrum, antibacterial antibodylike reaction by which some bacteria activate inflammatory cells. It is of interest that IgE also has this activity, and it suggests a different, perhaps beneficial, role of IgE in the activation of inflammatory cells.
S. aureus is the principal cause of hospital-acquired bacteremias (1) which, in some patients, result in septic and toxic shock syndromes (37) associated with hypotension, rash, and collapse. Furthermore, Staph A alone or immobilized on S. aureus Cowan 1 or on Sepharose has been used in serotherapy of cancer in humans (41) . During this treatment patients often suffer from symptoms similar to those observed during anaphylaxis (16, 44) . Histamine infusion in humans induces hypotension and skin rash (42, 43) , and Staph A injection produces systemic anaphylaxis in nonimmunized guinea pigs (5) . Therefore, the present results suggest that some of the symptoms associated with S. aureus bacteremia or serotherapy of cancer with Staph A are due to the release of histamine from peripheral blood basophils.
